BioPharmSignal logoBioPharmSignal

Biotech News

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

ImmunityBio (IBRX)ImmunityBioFDA / regulatory

Macau SAR, China regulator grants approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in patients with BCG-unresponsive NMIBC with CIS ± papillary tumors Authorization follows a reliance-based review referencing prior FDA and EMA decisions First ANKTIVA authorization in Asia, supporting

Open original release

Related news

IBRXImmunityBio2026-05-20 00:30 EST

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027

IBRXImmunityBio2026-05-22 11:30 EST

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS

ARGXArgenx2026-05-08 21:20 EST

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

BMYBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

INBXInhibrx2026-06-15 13:15 EST

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

COGTCogent Biosciences2026-05-28 12:00 EST

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

GSKGSK plc2026-05-18 07:00 EST

GSK’s RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased risk

BMYBMYBristol-Myers Squibb Company2026-05-08 10:59 EST

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

FATEFate Therapeutics2026-07-09 12:30 EST

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

REPLReplimune Group2026-05-29 12:00 EST

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

View all latest news

ImmunityBio

ImmunityBio is an immunotherapy company focused on cancer and immune-system activation, with a portfolio spanning cell therapy and biologics. Its story is built around creating broad anti-cancer immune responses.

Recent company news

IBRXImmunityBio2026-06-01 17:51 EST

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

IBRXImmunityBio2026-05-22 11:30 EST

ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation

IBRXImmunityBio2026-05-22 11:30 EST

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS

IBRXImmunityBio2026-05-20 00:30 EST

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027

IBRXImmunityBio2026-05-19 11:30 EST

ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026

Stock data

Close
6.99 USD
Market cap
7.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States